Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(121)
•••
Comment by JMark80on Nov 19, 2019 10:38pm
30 Views
Post# 30372293

RE:🚨 Warning : JOHNNYBRAVO1112 is a LIER/BASHER

RE:🚨 Warning : JOHNNYBRAVO1112 is a LIER/BASHER
Looking4Doubles wrote: For someone to post 29 times in less than 24 hours with comments like "F this" "F that" "moron" etc..
CLEARLY SHOWS the lack of intellect, diction and civility a sane person would have.  Please take or go back on your meds !  Your behavior is dangerous to your health.

Your failure to truthfully answer the basic question of "why you are even still on the site?" tells new investors all they need to know about your MOTIVE. 

NOONE is going to sell because of your 24/7 banter !  That should be CLEAR after 6 months ! ! (The company is clearly in negotiations with "multiple" companies. )           DEAL WITH IT  ! ! !


Penny must be intellectually disabled, but high functioning.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities